Last updated on July 2018

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Brief description of study

The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.

Detailed Study Description

This is an Open label, randomized, active control, parallel-group pilot trial to examine the effect of initiation of APIXABAN at days 0-3 (TIA), days 3-5 (small stroke) and days 7-9 (medium stroke) to decrease fatal and/or recurrent stroke/TIA in 120 subjects who have suffered a recent( 0 to 48 hours from symptoms) TIA, or small to medium ischemic stroke compared to standard of care warfarin treatment regimen. Subjects will be randomly assigned in a 1:1 ratio to one of two treatment arms (apixaban or warfarin). Subjects will be followed for a total of 180 days during from screening through monthly follow-up visits.

Clinical Study Identifier: NCT02283294

Contact Investigators or Research Sites near you

Start Over

Arthur Labovitz, MD

Tampa General Hospital
Tampa, FL United States
  Connect »

Arthur Labovitz, MD

University of South Florida
Tampa, FL United States
  Connect »

Marcus Stoddard, MD

University of Louisville
Louisville, KY United States
  Connect »

Bijal Mehta, MD

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, CA United States
  Connect »

Ravikiran Korabathina, MD

Bayfront Health St Petersburg
Saint Petersburg, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.